JP6099976B2 - 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法 - Google Patents

抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法 Download PDF

Info

Publication number
JP6099976B2
JP6099976B2 JP2012503682A JP2012503682A JP6099976B2 JP 6099976 B2 JP6099976 B2 JP 6099976B2 JP 2012503682 A JP2012503682 A JP 2012503682A JP 2012503682 A JP2012503682 A JP 2012503682A JP 6099976 B2 JP6099976 B2 JP 6099976B2
Authority
JP
Japan
Prior art keywords
antibody
fcrh5
sequence
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012503682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522513A (ja
JP2012522513A5 (enExample
Inventor
クリスティ エルキンズ，
クリスティ エルキンズ，
アンドリュー ポルソン，
アンドリュー ポルソン，
アレン エベンズ，
アレン エベンズ，
カメリア アダムス，
カメリア アダムス，
ビン ジェン，
ビン ジェン，
ジャガス， アール． ジュニュチュラ，
ジャガス， アール． ジュニュチュラ，
ジョ−アン ホンゴ，
ジョ−アン ホンゴ，
ヤン ウー，
ヤン ウー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6099976(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2012522513A publication Critical patent/JP2012522513A/ja
Publication of JP2012522513A5 publication Critical patent/JP2012522513A5/ja
Application granted granted Critical
Publication of JP6099976B2 publication Critical patent/JP6099976B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012503682A 2009-04-01 2010-03-31 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法 Expired - Fee Related JP6099976B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21175409P 2009-04-01 2009-04-01
US61/211,754 2009-04-01
US16621409P 2009-04-02 2009-04-02
US61/166,214 2009-04-02
PCT/US2010/029521 WO2010114940A1 (en) 2009-04-01 2010-03-31 Anti-fcrh5 antibodies and immunoconjugates and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015168182A Division JP2016028052A (ja) 2009-04-01 2015-08-27 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法

Publications (3)

Publication Number Publication Date
JP2012522513A JP2012522513A (ja) 2012-09-27
JP2012522513A5 JP2012522513A5 (enExample) 2013-05-16
JP6099976B2 true JP6099976B2 (ja) 2017-03-29

Family

ID=42236394

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012503682A Expired - Fee Related JP6099976B2 (ja) 2009-04-01 2010-03-31 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法
JP2015168182A Pending JP2016028052A (ja) 2009-04-01 2015-08-27 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015168182A Pending JP2016028052A (ja) 2009-04-01 2015-08-27 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法

Country Status (18)

Country Link
US (2) US8362213B2 (enExample)
EP (1) EP2414395A1 (enExample)
JP (2) JP6099976B2 (enExample)
KR (1) KR20120003478A (enExample)
CN (1) CN102369218B (enExample)
AR (1) AR076030A1 (enExample)
AU (1) AU2010232682A1 (enExample)
BR (1) BRPI1012560A2 (enExample)
CA (1) CA2756988A1 (enExample)
CL (1) CL2011002418A1 (enExample)
IL (1) IL215404A0 (enExample)
MX (1) MX2011010265A (enExample)
PE (1) PE20120877A1 (enExample)
RU (2) RU2583270C2 (enExample)
SG (1) SG174930A1 (enExample)
TW (1) TW201039846A (enExample)
WO (1) WO2010114940A1 (enExample)
ZA (1) ZA201107128B (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174992A1 (en) 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
CN102369218B (zh) 2009-04-01 2014-07-16 霍夫曼-拉罗奇有限公司 抗-FcRH5抗体和免疫缀合物以及应用方法
US8962804B2 (en) * 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
KR20200128601A (ko) * 2011-05-27 2020-11-13 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
EP3228325A1 (en) 2011-06-10 2017-10-11 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
ES2874493T3 (es) * 2013-02-08 2021-11-05 Novartis Ag Sitios específicos para modificar anticuerpos para generar inmunoconjugados
DK2982681T3 (en) 2013-03-29 2018-12-10 Sumitomo Dainippon Pharma Co Ltd WT1 ANTIGENPEPTIDKONJUGATVACCINE
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
RU2670748C9 (ru) 2013-06-24 2018-12-13 Аблбио Конъюгаты антител с лекарственными агентами, обладающие улучшенной стабильностью, и их применение
TWI725931B (zh) * 2013-06-24 2021-05-01 美商建南德克公司 抗ｆｃｒｈ５抗體
ES2726850T3 (es) 2013-10-11 2019-10-09 Mersana Therapeutics Inc Conjugados de proteína-polímero-fármaco
PL3054992T3 (pl) 2013-10-11 2020-01-31 Asana Biosciences, Llc Koniugaty białko-polimer-lek
HUE050156T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
AU2015314744A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
ES2832711T3 (es) 2014-10-31 2021-06-11 Abbvie Biotherapeutics Inc Anticuerpos anti-CS1 y conjugados anticuerpo fármaco
SG11201704550XA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
JP2018524295A (ja) * 2015-06-15 2018-08-30 ジェネンテック， インコーポレイテッド 抗体及び免疫複合体
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
CN107849145B (zh) 2015-06-16 2021-10-26 基因泰克公司 抗cd3抗体及其使用方法
AU2016280102B2 (en) 2015-06-16 2022-06-16 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
NZ743124A (en) * 2015-12-04 2022-11-25 Memorial Sloan Kettering Cancer Center Antibodies targeting fc receptor-like 5 and methods of use
JPWO2017188346A1 (ja) * 2016-04-27 2019-02-28 国立大学法人 東京大学 マイクロファイバーを用いた血中循環細胞の捕捉及び回収用材料及び当該材料を用いる方法
MA45407A (fr) * 2016-06-17 2019-04-24 Magenta Therapeutics Inc Compositions et méthodes de déplétion de cellules
MX2019005438A (es) 2016-11-15 2019-08-16 Genentech Inc Dosificacion para tratamiento con anticuerpos bispecificos anti-cd20 / anti-cd3.
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
WO2018237335A1 (en) * 2017-06-23 2018-12-27 VelosBio Inc. IMMUNOCONJUGUATED ROR1 ANTIBODIES
JP7407699B2 (ja) 2017-07-28 2024-01-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗体製剤
PL3666787T3 (pl) 2017-08-10 2024-04-29 Sumitomo Pharma Co., Ltd. Koniugaty przeciwciało-lek zawierające pochodną hemiasterliny
JP7202301B2 (ja) * 2017-08-10 2023-01-11 住友ファーマ株式会社 ヘミアスタリン誘導体及びこれらの抗体薬物複合体
US10766613B2 (en) * 2017-11-28 2020-09-08 Textron Innovations Inc. System and method for rotorcraft-weight-on-wheels flight state transition control
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
CR20200391A (es) 2018-02-08 2020-10-19 Genentech Inc Moléculas biespecíficas de unión al antígeno y métodos de uso
CN112292401A (zh) 2018-03-06 2021-01-29 英凯尔生物科技有限责任公司 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210123075A1 (en) 2018-06-08 2021-04-29 Novartis Ag Compositions and methods for immunooncology
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US12247245B2 (en) 2018-07-25 2025-03-11 Northeastern University Selectivity screening for antimicrobial compounds
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP7560255B2 (ja) * 2019-02-13 2024-10-02 住友ファーマ株式会社 ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬
CA3127312A1 (en) 2019-02-13 2020-08-20 Sumitomo Dainippon Pharma Co., Ltd. Hemiasterlin derivative having cysteine residue
WO2020166592A1 (ja) * 2019-02-13 2020-08-20 大日本住友製薬株式会社 ヘミアスタリン誘導体とその抗体薬物複合体
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009764A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
CA3145301A1 (en) 2019-07-08 2021-01-14 Imcare Biotech, Llc. Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
KR20220080098A (ko) 2019-09-11 2022-06-14 아임케어 바이오테크, 엘엘씨. 항-세린 프로테아제 억제제 카잘(spik) 항체의 에피토프
US11845799B2 (en) 2019-12-13 2023-12-19 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
AU2020405183A1 (en) 2019-12-18 2022-06-09 TeneoFour, Inc. Heavy chain antibodies binding to CD38
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20230365709A1 (en) 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
MX2023005130A (es) 2020-11-04 2023-05-25 Genentech Inc Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
IL302396A (en) 2020-11-04 2023-06-01 Genentech Inc Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN117597359A (zh) 2021-04-08 2024-02-23 马伦戈治疗公司 与tcr结合的多功能分子及其用途
JP2024515793A (ja) 2021-04-27 2024-04-10 ノバルティス アーゲー ウイルスベクター生産システム
IL306111A (en) 2021-04-30 2023-11-01 Hoffmann La Roche Dosage for combined treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody and anti-CD79B antibody for antiretroviral drugs
WO2022241235A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
KR20240099382A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
IL316049A (en) 2022-04-13 2024-11-01 Genentech Inc Musuntuzumab pharmaceutical preparations and methods of use
JP2025512342A (ja) * 2022-04-13 2025-04-17 ジェネンテック， インコーポレイテッド 治療用タンパク質の医薬組成物および使用方法
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024102948A1 (en) * 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
CN116199772B (zh) * 2022-11-16 2023-10-17 怡道生物科技(苏州)有限公司 Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用
WO2025235357A1 (en) 2024-05-06 2025-11-13 Rondo Therapeutics, Inc. Bispecific antibodies that bind to cd28 and nectin-4

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
AU689131B2 (en) 1993-10-01 1998-03-26 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivative
US20020132252A1 (en) 1997-06-16 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
ES2591102T3 (es) 1999-11-29 2016-11-24 The Trustees Of Columbia University In The City Of New York Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma
US7105149B1 (en) * 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
US20040005561A1 (en) 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
KR101008758B1 (ko) 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US7858330B2 (en) * 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7888478B2 (en) * 2002-09-11 2011-02-15 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
EP1482972A4 (en) 2001-11-20 2005-11-23 Seattle Genetics Inc TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES
EP1575514A2 (en) 2002-07-31 2005-09-21 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
CN103394083B (zh) * 2003-11-06 2017-07-18 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
JP4658967B2 (ja) 2003-12-24 2011-03-23 ジェネンテック， インコーポレイテッド 造血系起源の腫瘍の治療のための組成物と方法
CA2567520A1 (en) * 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
CN104447992A (zh) 2004-09-23 2015-03-25 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
WO2006039238A2 (en) * 2004-09-30 2006-04-13 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Irta2 antibodies and methods of use
US20070134243A1 (en) * 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
US7947839B2 (en) * 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
JP2008526260A (ja) * 2005-01-12 2008-07-24 メダレックス インコーポレーティッド Ｉｒｔａ−２抗体およびその使用法
RU2430112C2 (ru) * 2005-06-20 2011-09-27 Дженентек, Инк. Композиции и способы диагностики и лечения опухоли
WO2008109533A2 (en) * 2007-03-02 2008-09-12 Medarex, Inc. Human antibodies that bind multiple irta family proteins, and uses thereof
CN102369218B (zh) 2009-04-01 2014-07-16 霍夫曼-拉罗奇有限公司 抗-FcRH5抗体和免疫缀合物以及应用方法
SG174992A1 (en) * 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use

Also Published As

Publication number Publication date
RU2016110891A (ru) 2018-11-27
IL215404A0 (en) 2011-12-29
KR20120003478A (ko) 2012-01-10
US20130089497A1 (en) 2013-04-11
BRPI1012560A2 (pt) 2016-07-26
CN102369218B (zh) 2014-07-16
TW201039846A (en) 2010-11-16
EP2414395A1 (en) 2012-02-08
US8362213B2 (en) 2013-01-29
ZA201107128B (en) 2012-12-27
JP2016028052A (ja) 2016-02-25
SG174930A1 (en) 2011-11-28
MX2011010265A (es) 2011-10-11
AU2010232682A1 (en) 2011-11-10
WO2010114940A1 (en) 2010-10-07
JP2012522513A (ja) 2012-09-27
PE20120877A1 (es) 2012-08-06
RU2583270C2 (ru) 2016-05-10
CA2756988A1 (en) 2010-10-07
US9017951B2 (en) 2015-04-28
US20110171125A1 (en) 2011-07-14
HK1166805A1 (en) 2012-11-09
CN102369218A (zh) 2012-03-07
CL2011002418A1 (es) 2012-03-16
AR076030A1 (es) 2011-05-11

Similar Documents

Publication Publication Date Title
JP6099976B2 (ja) 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法
JP7208092B2 (ja) 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
JP6132548B2 (ja) 抗ＦｃＲＨ５抗体および免疫接合体および使用方法
JP6132357B2 (ja) ヒト化ＣＤ７９ｂ抗体およびイムノコンジュゲートならびにそれらの使用
KR101486615B1 (ko) 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
JP2010533496A5 (enExample)
HK1233668B (zh) 抗cd79b抗體和免疫偶聯物及使用方法
HK1233668A1 (en) Anti-cd79b antibodies and immunoconjugates and methods of use
HK1233668A (en) Anti-cd79b antibodies and immunoconjugates and methods of use
HK1197246B (en) Anti-cd79b antibodies and immunoconjugates and methods of use
HK1166805B (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
HK1171236B (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170222

R150 Certificate of patent or registration of utility model

Ref document number: 6099976

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees